The EPO’s May 2020 decision in G3/19, on the patentability of certain plants, was among the most controversial in the office’s history. Anna Gregson of Mathys & Squire explores the implications.
Yesterday’s UK Supreme Court decision in Kymab v Regeneron is expected to have profound implications for innovative life sciences companies, according to lawyers.
The CJEU’s many attempts to clarify the law around SPCs has created more questions than answers, as Katie Cambrook and Ben Millson of Bristows explain.
Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.
The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.
Foreign patents protecting COVID-19 treatments may stall efforts to protect citizens, says Mark Engelman of Hardwicke chambers.
The search for clarity goes on as Broad gears up for another set of legal challenges, as Claire Irvine, partner at HGF, explains.
Ahead of the IQPC - Life Science IP conference in London, Kevin Mooney, chairman of the rules and procedure committee at the UPC, answers pressing questions on the IP landscape post-Brexit and the future of the Europe-wide patents court project.
The special 25th anniversary BIO-Europe 2019 global life science partnering event will be held November 11–13, 2019, in Hamburg, Germany.
As lawyers and industry prepare for a possible no-deal Brexit, the uncertainty surrounding its impact is palpable, as LSIPR’s Saman Javed discovers.